当前位置:首页 >财报库 > 报告详情

麦克森Mckesson(MCK)2026财年第三季度财务业绩电话会演示报告「NYSE」(英文版)(34页).pdf

上传人: 1****1 编号:1180574 2026-04-03 34页 572.08KB

下载:

1、 2026 McKesson Corporation.All rights reserved.1McKesson CorporationThird Quarter Fiscal 2026Earnings CallFebruary 4,2026 2026 McKesson Corporation.All rights reserved.2Cautionary StatementsThis presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act

2、of 1933 and Section 21E of the Securities Exchange Act of 1934.Forward-looking statements may be identified by their use of terminology such as“believes,”“expects,”“anticipates,”“may,”“will,”“should,”“seeks,”“approximately,”“intends,”“projects,”“plans,”“estimates,”“targets,”or the negative of these

3、words or other comparable terminology.Any discussion of our intent to separate our Medical-Surgical Solutions segment into an independent company,other anticipated or completed transactions,including the anticipated closings thereof,or synergies expected therefrom,litigation outcomes,financial outlo

4、ok,guidance,trends,strategy,plans,assumptions,expectations,commitments,and intentions may also include forward-looking statements.Readers should not place undue reliance on forward-looking statements,such as financial performance forecasts,which speak only as of the date they are first made.Except t

5、o the extent required by law,we undertake no obligation to update or revise our forward-looking statements.Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected,anticipated,or implied.Although it is not possible to predic

6、t or identify all such risks and uncertainties,we encourage investors to read the risk factors described in our publicly available filings with the Securities and Exchange Commission and news releases.These risk factors include,but are not limited to:we experience costly and disruptive legal dispute

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
1. **业绩表现**:Q3营收1062亿美元(同比+11%),调整后每股收益9.34美元(同比+16%);FY26调整后EPS指引上调至38.80-39.20美元(原38.35-38.85美元),预计增长17%-19%。 2. **业务亮点**:肿瘤与多专科平台营收增长37%,北美制药增长9%,处方技术解决方案增长9%;医疗外科解决方案营收微增1%。 3. **战略进展**:完成医疗外科解决方案分拆计划,退出欧洲业务;Health Mart获美国药剂师协会奖项。 4. **资本部署**:FY26计划回购25亿美元股票,剩余授权54亿美元;自由现金流预期44-48亿美元。 5. **风险提示**:包含前瞻性声明,涉及诉讼、供应链、网络安全等风险,实际结果可能存在差异。
**增长动力何在?** **风险有哪些?** **未来展望如何?**
客服
商务合作
小程序
服务号
折叠